U.S. FDA Approves Roche/Chugai's Actemra For Second-line RA

Roche Japanese subsidiary Chugai's novel interleukin-6 inhibitor Actemra gained U.S. FDA approval Jan. 8 for treating patients with moderately to severely active rheumatoid arthritis for whom TNF blockers aren't working - a good beginning but still a ways from the first-line indication the pharma sought and still hopes to gain using data from its risk management programs and other sources